Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04930900 | Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection | PHASE1 | COMPLETED | 15 | — | — | Aug 9, 2021 | Jul 25, 2022 | Jul 29, 2022 | 1 | Australia |
Blood samples will be collected to measure plasma concentrations of adrenaline
Blood samples will be collected to measure plasma concentrations of adrenaline
Blood samples will be collected to measure plasma concentrations of adrenaline
| Arm | Type | Description |
|---|---|---|
| ARS-1 with URTI | EXPERIMENTAL | ARS-1 with URTI |
| ARS-1 without URTI | EXPERIMENTAL | ARS-1 without URTI |
| Name | Type | Description |
|---|---|---|
| ARS-1 with URTI | DRUG | ARS-1 |
| ARS-1 without URTI | DRUG | ARS-1 without URTI |
Inclusion Criteria: * Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on the clinical judgement and the positive infectious cause of URTI to be confirmed by Respiratory Pathogens Panel. * Has body weight more than 55 kg for male and 50 kg for female and body mass in...